Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations

Slide collection

220,351-220,380 of 319,975

filter-aware
24
The slide uses a biological signaling pathway map to justify combination therapy strategy.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
25
The diagram shows the RAS/MAPK signaling pathway. The table provides a breakdown of patient populations for specific indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
26
The slide uses two tables to demonstrate competitive advantage in potency and pharmacokinetics.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
27
The diagram shows the signaling pathway with specific drug targets highlighted.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
28
The slide compares tumor volume reduction across two different CDX models (WiDr and RKO) using various treatment regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
29
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
30
Data cut 23MAR2023. TRAE = Treatment-related Adverse Event. EC = Encorafenib + Cetuximab.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
31
The slide uses a process-oriented flow to demonstrate clinical validation milestones.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
32
The slide highlights selectivity and potency, using arrows to indicate performance relative to the competitor.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
33
Data presented as tumor volume over time (days) with error bars representing SEM.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
34
Includes RECIST 1.1 criteria reference and specific patient history.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
35
The table compares 'ALL' vs 'Gr >= 3' adverse events for different dosing regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
36
The diagram shows the EGFR signaling pathway and the inhibitory effect of ERAS-801.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
37
The slide uses a stacked bar chart to show mutation incidence and a comparison table to contrast clinical outcomes across different indications.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
38
The slide uses Western blot data to demonstrate potency and a table to demonstrate pharmacokinetic superiority.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
39
The chart is a Kaplan-Meier survival plot. The comparison shows ERAS-801 (blue line) outperforming standard EGFR inhibitors (Erlotinib, Lapatinib, Osimertinib) and vehicle control.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
40
The slide displays four distinct survival plots (HK301, GS025, HK336, GS187) showing statistically significant survival improvements (***) with ERAS-801 treatment.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
41
The slide uses a waterfall plot to show individual model responses and pie charts to summarize efficacy across the total cohort vs. the specific EGFR-mutant/amplified subset.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
42
The slide uses a table format to communicate a product roadmap for clinical development.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Erasca's pipeline and clinical data1 hit
43
Erasca | Investor Presentation Deck | 56 slidesErasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Potential impact and investment thesis1 hit
44
Features the Erasca logo and a Lorenz attractor-style graphic.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations Beat · Potential impact and investment thesis1 hit
45
The slide uses a matrix-like layout to compare drug candidates by development stage and company, with a callout box for competitive advantages.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
46
The slide uses a bullseye/concentric circle framework to communicate strategic prioritization of clinical trials.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
47
The slide uses a contrast-based layout to frame the subject as a winner in a difficult therapeutic space.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
48
The slide uses western blot data to demonstrate the superiority of ERAS-007 in a specific biological pathway context.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
49
Includes RECIST 1.1 criteria reference and patient progression note.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
50
The chart displays individual patient responses to treatment, with bars colored by dosage level.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
51
The chart displays individual patient treatment timelines, with markers for partial response, stable disease, and progressive disease.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
52
Data from HERKULES-1 study, cutoff 23 May 2022.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit
53
The slide uses a line chart to show concentration over time and a table to summarize key PK metrics (Cmax, Cmin, T>IC90, T<IC50) for five different dosing regimens.Erasca | Investor Presentation Deck | 56 slides · Erasca
Pitch deck Investor relations 1 hit